University of Nebraska

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Nebraska sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).

407 total trials 51 currently recruiting 261 completed early-phase tilt top decile by trial count

University of Nebraska: 407 sponsored US clinical trials, 51 recruiting.

University of Nebraska sponsors 407 registered US clinical trials on ClinicalTrials.gov, 51 of them currently recruiting, and 261 completed. 31 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Arterial Disease, with 7 trials.

Top-decile sponsor footprint

University of Nebraska ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 36/100

261 of 332 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

407 total, page 4 of 9

COMPLETED NA

Mother and Child Health Outcomes After Maternal Bariatric Surgery

NCT03297307
TERMINATED NA

Variable Visual Stimulus as a Novel Approach for Gait Rehabilitation

NCT03737331
COMPLETED NA

Impacts of a Combined Berry Extract Supplement on Vascular Function and Oxygen Utility Capacity in Young Adults

NCT04312022
COMPLETED NA

Examining Reach and Implementation of an Evidence-based Weight Loss Program in Rural Primary Care

NCT03690557
COMPLETED NA

Headsprout Reading Program in Children With Autism Spectrum Disorder and Reading Delay

NCT03055533
COMPLETED Phase 2

Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

NCT03616184
COMPLETED NA

Dietary Nitrate Supplementation and Thermoregulation

NCT03506646
COMPLETED NA

Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients

NCT03506633
COMPLETED NA

Whole-of-Community Youth Population Physical Activity

NCT03380143
TERMINATED NA

Loop Duodenal Switch: Outcomes at One Year

NCT03206736
COMPLETED NA

CALLiNGS Protocol: Care Across Locations Longitudinally in Navigation of Goals and Symptoms

NCT03999957
COMPLETED NA

Engaging Rural Men With Mobile Technologies for Weight Loss

NCT03329079
COMPLETED NA

Mobility Exercises for Gait (MEG Neuroplasticity Project)

NCT03555708
TERMINATED NA

Infantile Colic: Study of the Efficacy of Lactobacillus GG (ATCC 53103) Plus Chamomile in Breastfeeding Infants

NCT03477669
TERMINATED Phase 1

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

NCT03201250
COMPLETED NA

Effect of the DentalVibe Injection System on Pain During Local Anesthesia Injections in Children

NCT03374982
COMPLETED NA

Facilitating Oncology Patient-Clinician Communication Via E-health Innovations

NCT03442127
COMPLETED

Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study

NCT03683004
COMPLETED Phase 1

A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

NCT03270969
COMPLETED NA

Variability of Movement on an Altered Inertial Dynamics Task

NCT04505527
COMPLETED

The Patients' Experience After Stem Cell Transplant

NCT03454568
COMPLETED NA

Impact of Oral Hygiene Gels on Peri-implant Mucositis

NCT03243591
TERMINATED

Role of Circulating Innate Lymphoid Cells in Allergic Disorders

NCT03069495
COMPLETED NA

Oxygen Transport in Normobaric vs. Hypobaric Hypoxia

NCT03335917
COMPLETED NA

Reducing Distress and Depressive-symptoms in Rural Women

NCT03465813
COMPLETED NA

Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis

NCT02902211
COMPLETED Phase 2

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

NCT03226418
COMPLETED Phase 4

Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic

NCT03431831
COMPLETED

Effect of Different Viscous Foods and Liquids on Swallowing Sounds

NCT03024333
TERMINATED NA

Use of Reactivated DEFINITY or LUMASON in Patients Undergoing Rest or Stress Echocardiography

NCT02950493
COMPLETED Early Phase 1

Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

NCT02972788
COMPLETED Phase 2

Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders

NCT02824627
COMPLETED

Long Term Outcomes Follow-up of Glenoid Anchor Peg Component Fixation

NCT02983357
COMPLETED Phase 2

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02874404
COMPLETED

Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery

NCT02767388
TERMINATED NA

Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control

NCT02483572
COMPLETED Phase 4

Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

NCT02759861
COMPLETED NA

Intensive Referral to Reduce Smoking in Probationers

NCT03042650
COMPLETED NA

Shared Medical Visits for Spanish-speaking Patients With Type 2 Diabetes

NCT02836015
COMPLETED NA

Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit

NCT02680743
COMPLETED

Validation of a Revised Food Frequency Questionnaire

NCT02693184
TERMINATED Phase 1

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

NCT02833701
COMPLETED NA

Balance Training for Elders With Heart Failure

NCT02566785
TERMINATED Phase 4

Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia

NCT02647892
COMPLETED

Stress, Coping and Health Behaviors in Pregnancy

NCT02705235
TERMINATED Phase 4

Post-tonsillectomy Pain Control in Adults

NCT02358850
COMPLETED Phase 2

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

NCT02654119
COMPLETED NA

Simplified Diet Approach in Phenylketonuria

NCT02555579
COMPLETED NA

Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency

NCT02553447
COMPLETED Phase 1

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

NCT02561273
← Previous Page 4 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 57
Phase 2 52
Phase 3 10
Phase 4 21

Therapeutic Areas

Peripheral Arterial Disease 7
Lymphoma 6
Breast Cancer 5
Rheumatoid Arthritis 5
Peripheral Artery Disease 3
Multiple Myeloma 3
Healthy 3
Sleep Fragmentation 2
Graft-versus-host Disease (GVHD) 2
Parkinson's Disease 2

What is open in the University of Nebraska pipeline

51 recruiting of 407 indexed (13% open); 261 completed (64%).

Phase mix: 31 late (III/IV) vs 109 early (I/II) (early-phase heavy).

Top condition: Peripheral Arterial Disease (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Nebraska: open-pipeline peers nationwide

Peers matched on 407 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 10%15%20%25% Total trials Recruiting share University of NebraskaCase Comprehensive Cancer CenterTakedaUniversity of Kansas Medical CenterSt. Jude Children's Research HospitalAddario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 407 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Nebraska page

407 registered trials is a research-attention snapshot, not an endorsement of University of Nebraska or any single study.

  • 51 of University of Nebraska's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Peripheral Arterial Disease is the condition University of Nebraska studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Arterial Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Nebraska pipeline card: 407 registered trials from official public datasets.Report a data error.